1. Distinct Mechanisms of Idiopathic and Thienopyridine-Assocaited Thrombotic Thrombocytopenia Purpura: Final Results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study
- Author
-
J.L. Winters, Anaadriana Zakarija, Ravindra Sarode, Paul R. Yarnold, Hau C. Kwaan, Ivy Weiss, June M. McKoy, Bruce C. McLeod, Elizabeth A. Richey, Joseph E. Kiss, Nicholas Bandarenko, Robert C. Soltysik, Charles L. Bennett, Patricia Carey, Thomas L. Ortel, Thanh Ha Luu, Constance Danielson, Gail Rock, Dilip K. Pandey, Thomas Raife, John F. Cursio, William F. Clark, and Dennis W. Raisch
- Subjects
medicine.medical_specialty ,Creatinine ,Thienopyridine ,business.industry ,Immunology ,Thrombotic thrombocytopenic purpura ,Autoantibody ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Gastroenterology ,ADAMTS13 ,chemistry.chemical_compound ,chemistry ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Von Willebrand disease ,Platelet ,Rituximab ,business ,medicine.drug - Abstract
Background : Many idiopathic thrombotic thrombocytopenia purpura (TTP) patients have severe deficiency of ADAMTS13, an enzyme that cleaves ultralarge von Willebrand multimers. We recently reported that thienopyridine-associated TTP is characterized by an immunologic pathway with severe ADAMTS13 deficiency and a non-immunologic pathway with higher ADAMTS13 activity levels. We now compare findings for idiopathic and thienopyridine-associated TTP patients. Methods : Clinical findings and laboratory findings were evaluated for 51 idiopathic and 39 thienopyridine-associated TTP. Results: Clinical findings were similar between idiopathic and thienopyridine-associated TTP for both severe ADAMTS13 deficient and non-deficient patients. Differences were noted in gender and age, relapse rates, and survival. Conclusion : Among TTP patients with ADAMTS13 deficiency, relapses are frequent in idiopathic TTP patients and Rituximab may be useful, while for thienopyridine-associated TTP patients spontaneous relapse are rare as long as no re-exposure occurs. Among ADAMTS13 non-deficient patients, survival is high following therapeutic plasma exchange (TPE) for idiopathic patients but not for thienopyridine-associated TTP patients. Despite similarities, idiopathic and thienopyridine associated TTP probably have different initiating factors. ADAMTS13 activity and clinical characteristics in idiopathic and thienopyridine-associated TTP Idiopathic severe ADAMTS13 deficiency (n=29) †Thienopyridine severe ADAMTS13 deficiency (n=26) Idiopathic non-severe ADAMTS13 deficiency (n=22) †Thienopyridine non-severe ADAMTS13 deficiency (n=13) *p2.5 mg/dl* 11% 27% 48% 46% 30-day survival 96% 85% 90% 62% Long-term relapse* 42% 8% 0% 0% Neutralizing autoantibodies to ADAMTS13 (prior to TPE) § 79% 100% 27% 0% Neutralizing autoantibodies to ADAMTS 13 (measured at remission) § 55% 33%‡ 33% 0%
- Published
- 2008